Page last updated: 2024-12-08
fr 66973
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
FR 66973: antitumor antibiotic from Streptomyces sandaensis; more potent against B16 melanoma & P388 leukemia than mitomycin C; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 133974 |
MeSH ID | M0155230 |
Synonyms (15)
Synonym |
---|
fr66973 |
113202-60-1 |
fk-973 |
fr-66973 |
fk 973 |
fk973 |
fr 66973 |
3,9-epoxy-3h-azirino(2,3-c)(1)benzazocine-5-carboxaldehyde, 1-acetyl-7,9-bis(acetyloxy)-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,9,9a-hexahydro- |
ccris 6861 |
11-acetyl-4-formyl-8-carbamoyloxymethyl-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12 ]tetradeca-2,4,6-trien-6,9-diyl diacetate |
11-acetyl-8-carbamoyloxymethyl-4-formyl-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12 ]tetradeca-2,4,6-trien-6,9-diyl diacetate |
14-oxa-1,11-diazatetracyclo[7.4.1.0(2,7).0(10,12)]tetradeca-2,4,6-triene, 11-acetyl-6,9-bis(acetyloxy)-4-formyl-8-[(aminocarbonyloxy)methyl]- |
1-acetyl-5-formyl-8-{[hydroxy(imino)methoxy]methyl}-1,1a,2,9a-tetrahydro-3,9-epoxyazireno[2,3-c][1]benzazocine-7,9(8h)-diyl diacetate |
DTXSID10921015 |
[11-acetyl-9-acetyloxy-8-(carbamoyloxymethyl)-4-formyl-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12]tetradeca-2(7),3,5-trien-6-yl] acetate |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (16)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 7 (43.75) | 18.7374 |
1990's | 7 (43.75) | 18.2507 |
2000's | 1 (6.25) | 29.6817 |
2010's | 1 (6.25) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.36
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.36) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (5.56%) | 5.53% |
Reviews | 1 (5.56%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 16 (88.89%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |